智通财经网·2026-02-11 10:05Core Viewpoint - Shanghai Pharmaceuticals (02607) has received approval from the National Medical Products Administration for the production of Tamsulosin hydrochloride, a drug used to treat benign prostatic hyperplasia (BPH) [1] Group 1: Company Developments - The approval for Tamsulosin hydrochloride indicates that the raw material meets domestic drug registration requirements and can be sold in the domestic market [1] - The company has invested approximately RMB 1.5 million in research and development for this drug [1] - The approval process has provided valuable experience for the company in future raw material drug applications [1] Group 2: Product Information - Tamsulosin hydrochloride is a third-generation ultra-selective long-acting α1 inhibitor, originally developed by Japan's Yamanouchi Pharmaceutical and approved by the FDA in July 1992 [1] - The company submitted the registration application for this drug to the National Medical Products Administration in July 2024, which was accepted [1] Group 3: Financial Impact - The approval of Tamsulosin hydrochloride is not expected to have a significant impact on the company's current operating performance [1]